Variations in the binding of mammalian fibrinogens to streptococci of different animal origin.

The research investigates how streptococci bacteria, from various animals, bind to fibrinogens, a protein involved in the clotting of blood. The findings reveal that all 59 randomly chosen streptococcal cultures adhere more to human fibrinogen than others, except for Sc. dysgalactiae, a streptococcus strain that shows higher affinity to bovine fibrinogen and relatively more to equine, canine and ovine fibrinogen.

Research Method

• The researchers conducted a quantitative study to evaluate the binding of 125I-labelled fibrinogen from humans, cows (bovines), horses (equines), dogs (canines), and sheep (ovines) by streptococci of serological groups A, B, C, and G.
• A pool of 59 randomly selected streptococcal cultures were tested for their affinity towards fibrinogen from these five species.

Key Findings

• All streptococcal cultures generally showed higher binding to human fibrinogen compared to the others. This suggests that streptococci have greater affinity towards human fibrinogen.
• The Sc. dysgalactiae strain was unique in that it demonstrated a higher affinity for bovine fibrinogen than human fibrinogen. It also showed a distinct ability to bind more fibrinogen from horses, dogs, and sheep compared to other streptococci, indicating a broad affinity.
• Some cultures of Sc. equi and Sc. zooepidemicus, other strains of streptococci, also had high binding activities towards equine fibrinogen, showing specific affinity to horse fibrinogen.
• Streptococci of group B, however, exhibited a low binding capacity, particularly with horse and dog fibrinogens. This suggests that Bstreptococci may have less potential to infect or cause diseases in these species.

Implications of the Research

• This research contributes to the understanding of the host-pathogen interaction between streptococci and different animal species, providing valuable insights into the organism’s infection dynamics.
• These findings could be instrumental in the production of more specific vaccines or therapies against streptococci infections in various hosts. For example, drugs targeting the Sc. dysgalactiae strain might be more effective in cows than in humans or other animals.